75 results
8-K
EX-99.1
TSHA
Taysha Gene Therapies Inc
10 Jan 24
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
12:00am
expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential benefits and clinical
8-K
EX-10.1
lluxp2sfviqrlvlux
20 Dec 23
Departure of Directors or Certain Officers
4:21pm
S-8
EX-99.1
36yrie5jixqrlaku5rq
20 Dec 23
Registration of securities for employees
4:20pm
8-K
EX-99.1
d3ffe1
26 Sep 23
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
8:08am
8-K
EX-99.1
iyo0p4z7hb3dt6zk9k
19 Sep 23
Taysha will pursue external strategic options for the TSHA-120 program to potentially enable further program development
4:09pm
8-K
EX-99.1
ndi0vs
24 Aug 23
Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
8:09am
8-K
EX-10.1
wymnaimk6 jj8hi
14 Aug 23
Entry into a Material Definitive Agreement
7:29am
8-K
EX-99.1
qwbu exc0lm6vnx
19 May 23
Other Events
8:28am
PRE 14A
1afj 1wsxsmrhao30tq
27 Apr 23
Preliminary proxy
4:03pm